The treatment of Alzheimer's disease: Success short of cure

Kenneth Rockwood, Michael Wallack, Raymond Tallis

Producción científica: Contribución a una revistaComentario/debaterevisión exhaustiva

27 Citas (Scopus)

Resumen

Metaphor has an important role in the discussion of scientific discovery because it enables researchers to talk about things of which their understanding is incomplete. Alzheimer's disease (AD) can be seen as a journey down a path, which becomes steadily less pleasant and ends in a wholly undesirable destination. To further the metaphor, treatments can be seen as attempts to help the patient return to the starting point, to slow the journey, or to stop at some point on the path. However, treatment may be successful but may not return the patient to their starting point or slow disease progression. We argue that treatments that steer the patient down a different path, to a destination preferable to that at the end of the AD path, can also be seen as successful. This metaphor has practical implications for clinical trials. It highlights the importance of individualised outcome measures that incorporate patients' preferences and should encourage us to develop better means of enabling the recovery of self. To understand how there can be treatment success short of cure, without knowing at the outset what form that success may take, will require systematic observation and careful description of patients' experiences.

Idioma originalEnglish
Páginas (desde-hasta)630-633
Número de páginas4
PublicaciónThe Lancet Neurology
Volumen2
N.º10
DOI
EstadoPublished - oct. 1 2003

Nota bibliográfica

Funding Information:
KR has had research contracts from, and conducted clinical trials, on anti-dementia drugs for Aventis, Janssen-Ortho, Novartis, and Pfizer, and presently does occasional consulting work for each of the last three. This paper arose from the Fifth Annual Halifax Symposium on the Treatment of Alzheimer's Disease, which is sponsored in part with grants from Janssen-Ortho, Lundbeck, Merck, Novartis, Pfizer, and Servier. RT and MW have also been sponsored to attend these meetings.

Funding Information:
KR is supported by an Investigator Award from the Canadian Institutes of Health Research, and by the Dalhousie Medical Research Foundation as Kathryn Allen Weldon Professor of Alzheimer Research.

ASJC Scopus Subject Areas

  • Clinical Neurology

Huella

Profundice en los temas de investigación de 'The treatment of Alzheimer's disease: Success short of cure'. En conjunto forman una huella única.

Citar esto